Business Description
enGene Therapeutics is a Canadian biotechnology company focused on developing gene-based treatments for bladder cancer. Its leading drug candidate, detalimogene voraplasmid, is being developed as a standalone treatment for a form of bladder cancer that has not spread into the muscle wall. The company also has a second treatment called LEGEND currently in Phase 2 clinical testing. enGene Therapeutics is headquartered in Montreal, Canada.
